Eleven Biotherapeutics reported 8.98M in Selling and Administration Expenses for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Amgen AMGN:US $ 1.23B 197M
Bayer BAYN:GR 3.94B 346M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Corcept Therapeutics CORT:US $ 37.55M 5.26M
Eleven Biotherapeutics EBIO:US 8.98M 379K
Eli Lilly And LLY:US $ 1.56B 34.1M
Intrexon XON:US $ 19.58M 2.81M
Merk MRK:US $ 2.3B 518M
Rigel Pharmaceuticals RIGL:US $ 27.4M 2.89M
Ziopharm Oncology ZIOP:US $ 3.5M 1.41M